GMAB News and Press, Genmab A/S From 04/17/23

Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Genmab A/S (Nasdaq: GMAB) and argenx (Euro...

Genmab A/S press release ( GMAB ): FY GAAP EPS of DKK83.65. Revenue of DKK14.6B (+72.2% Y/Y). Outlook: Genmab expects its 2023 revenue to be in the range of DKK 14,600–16,100 million, compared to DKK 14,595 million in 2022. Genmab’s projected revenue for 202...

Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Ch...

Company Announcement Repurchase of up to 2 2 0,000 shares H onoring commitments under our Restricted Stock Unit program Completion expected on March 31 , 2023 COPENHAGEN , Denmark; February 22, 20 2 3 ...

Company Announcement COPENHAGEN , Denmark; February 22, 2023 – Genmab A/S ( Nasdaq: GMAB ) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in 2022, financial performance for the year an...

Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...

Summary Genmab (GMAB) is a Danish commercial biopharma company with a leading technology and track record in innovative antibody-based therapeutics. Darzalex royalty revenue is the key driver of the stock price and the bedrock of Genmab's strong performance during 2021-2022. We expe...

Company Announcement Net sales of DARZALEX ® in 2022 totaled USD 7, 977 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc . (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof. ...

Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...